ATM and gastric cancer: The research group compared the efficacy of olaparib plus paclitaxel (olaparib/paclitaxel) versus paclitaxel alone (placebo/paclitaxel) in patients with advanced-stage/metastatic GC and evaluated whether a low ATM expression was a predictor of improved clinical outcomes in patients treated with olaparib/paclitaxel.